These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 15688602)

  • 1. Target selection issues in drug discovery and development.
    Sausville EA
    J Chemother; 2004 Nov; 16 Suppl 4():16-8. PubMed ID: 15688602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The opportunities and challenges of personalized genome-based molecular therapies for cancer: targets, technologies, and molecular chaperones.
    Workman P
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S45-56. PubMed ID: 12819933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The development of molecularly targeted anticancer therapies: an Eli Lilly and Company perspective.
    Perry WL; Weitzman A
    Clin Adv Hematol Oncol; 2005 Mar; 3(3):199-202, 237-8. PubMed ID: 16166991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Optimizing target selection and development strategy in cancer treatment: the next wave.
    Sausville EA
    Curr Med Chem Anticancer Agents; 2004 Sep; 4(5):445-7. PubMed ID: 15379701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumour-targeted drug and gene delivery: principles and concepts.
    Cassidy J; Schätzlein AG
    Expert Rev Mol Med; 2004 Sep; 6(19):1-17. PubMed ID: 15387893
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical and clinical experience of antisense therapy for solid tumors.
    Webb MS; Zon G
    Curr Opin Mol Ther; 1999 Aug; 1(4):458-63. PubMed ID: 11713760
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Are targeted therapies really targeted?
    Schilsky RL
    Clin Adv Hematol Oncol; 2003 Dec; 1(12):722-3. PubMed ID: 16258475
    [No Abstract]   [Full Text] [Related]  

  • 8. Strategy for the development of novel anticancer drugs.
    Saijo N; Tamura T; Nishio K
    Cancer Chemother Pharmacol; 2003 Jul; 52 Suppl 1():S97-101. PubMed ID: 12856152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anticancer drug discovery in the future: an evolutionary perspective.
    Ma X; Wang Z
    Drug Discov Today; 2009 Dec; 14(23-24):1136-42. PubMed ID: 19800414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecules for the millennium: how will they look? New drug discovery year 2000.
    Sausville EA; Johnson JI
    Br J Cancer; 2000 Dec; 83(11):1401-4. PubMed ID: 11076644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug development for cancer chemoprevention: focus on molecular targets.
    Johnson KA; Brown PH
    Semin Oncol; 2010 Aug; 37(4):345-58. PubMed ID: 20816505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discovery of novel drugs for promising targets.
    Martell RE; Brooks DG; Wang Y; Wilcoxen K
    Clin Ther; 2013 Sep; 35(9):1271-81. PubMed ID: 24054704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ProLindac (AP5346): a review of the development of an HPMA DACH platinum Polymer Therapeutic.
    Nowotnik DP; Cvitkovic E
    Adv Drug Deliv Rev; 2009 Nov; 61(13):1214-9. PubMed ID: 19671439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The contemporary drug development process: advances and challenges in preclinical and clinical development.
    Garrett MD; Walton MI; McDonald E; Judson I; Workman P
    Prog Cell Cycle Res; 2003; 5():145-58. PubMed ID: 14593708
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modern molecular approaches to drug design and discovery.
    Ojima I
    Acc Chem Res; 2008 Jan; 41(1):2-3. PubMed ID: 18193819
    [No Abstract]   [Full Text] [Related]  

  • 16. Resisting a fundamentalist policy.
    Castro M
    J Clin Oncol; 2005 May; 23(15):3645-6; author reply 3646-8. PubMed ID: 15908688
    [No Abstract]   [Full Text] [Related]  

  • 17. RNA interference screening for the discovery of oncology targets.
    Quon K; Kassner PD
    Expert Opin Ther Targets; 2009 Sep; 13(9):1027-35. PubMed ID: 19650760
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SRC as a potential therapeutic target in solid tumor oncology.
    Gallick GE
    Clin Adv Hematol Oncol; 2004 Jul; 2(7):435-7. PubMed ID: 16163218
    [No Abstract]   [Full Text] [Related]  

  • 19. The role of the National Cancer Institute in drug development.
    Doroshow J
    Clin Adv Hematol Oncol; 2005 Apr; 3(4):257-8. PubMed ID: 16166997
    [No Abstract]   [Full Text] [Related]  

  • 20. Chemotherapy sensitivity and response assays: are the ASCO guidelines for clinical trial design too restrictive?
    Wieand HS
    J Clin Oncol; 2005 May; 23(15):3643-4; author reply 3646-8. PubMed ID: 15908687
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.